Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.


In order to optimize the clinical application of an increasing number of proteasome inhibitors, investigations into the differences between their respective pharmacodynamic and pharmacokinetic profiles, including their ability to act as a perpetrator in drug-drug interactions, are warranted. Therefore, in the present in vitro study, it was investigated… (More)
DOI: 10.3892/ol.2017.6560


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.